Form 4 for AKTS Aktis Oncology, Inc.
Accepted 2026-01-14 00:00:00 ET · period of report 2026-01-12 · accession 0001473930-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-01-14 | 2026-01-12 | AKTS | Foley Todd | Dir, 10% | C - Cnv Deriv | — | +4.00M | 4.00M | New | — |
| DI | 2026-01-14 | 2026-01-12 | AKTS | Foley Todd | Dir, 10% | P - Purchase | $18.00 | +232.9K | 4.24M | +6% | +$4.19M |
| DMI | 2026-01-14 | 2026-01-12 | AKTS | Foley Todd | Dir, 10% | C - Cnv Deriv | $0.00 | -15.23M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-12 | C | A | 2,688,270 | — | 3,285,661 | I See Footnote | — | — | (F5) The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018. (F2) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. (F6) The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| 2 | Common | Common Stock | 2026-01-12 | P | A | 232,870 | $18.00 | 4,235,403 | I See Footnote | — | — | (F9) The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. (F10) The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018. |
| 3 | Common | Common Stock | 2026-01-12 | C | A | 597,391 | — | 597,391 | I See Footnote | — | — | (F1) The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC. (F2) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. (F4) The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| 4 | Common | Common Stock | 2026-01-12 | C | A | 716,872 | — | 4,002,533 | I See Footnote | — | — | (F7) The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018. (F2) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. (F8) The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018. |
| 5 | Derivative | Series Seed Redeemable Convertible Preferred Stock | 2026-01-12 | C | D | 2,272,727 | $0.00 | 0 | I See Footnote | — · — to — | 597,391 Common Stock | (F2) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. (F1) The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| 6 | Derivative | Series B Redeemable Convertible Preferred Stock | 2026-01-12 | C | D | 2,727,273 | $0.00 | 0 | I See Footnote | — · — to — | 716,872 Common Stock | (F2) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. (F7) The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| 7 | Derivative | Series A Redeemable Convertible Preferred Stock | 2026-01-12 | C | D | 10,227,273 | $0.00 | 0 | I See Footnote | — · — to — | 2,688,270 Common Stock | (F2) Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. (F3) The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. (F5) The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018. |